2nd Annual Oligonucleotides for CNS Summit

Temas de la conferencia
With Biogen investing millions in Ionis' efforts to weaponize ASOs against SMA, Stoke Therapeutics collaborating with Acadia Pharmaceuticals to supercharge the development of RNA-Based treatments for genetic neurodevelopmental diseases and the global oligonucleotide therapeutics market set to experience unprecedented growth, there’s never been a more opportune moment for biopharma to expand their oligonucleotide pipelines into the untapped potential of the CNS.

Organizador profesional (PCO)
Hanson Wade

https://go.evvnt.com/1054624-2?pid=4832

Ms. Stephanie Nketia